#886
|
|||
|
|||
Öèòàòà:
Îäíà êàðòèíêà çàìåíÿåò òûñÿ÷ó ñëîâ [Èçîáðàæåíèÿ äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì] À ïî ïîâîäó FDA, âñïîìèíàþ ñòàðûé åâðåéñêèé àíåêäîò. ×òî-òî ÿ ñåãîäíÿ èì íå äîâåðÿþ. |
#887
|
||||
|
||||
 êà÷åñòâå êèò÷à: ñëûøàë, ÷òî íà ðûíîê âûïóñêàþò àíòàãîíèñò äàáèãàòðàíà íà îñíîâå ìîíîêëîíàëüíûõ àíòèòåë. Ãîâîðÿò, ÷òî ýôôåêò ìîìåíòàëüíûé - îò îäíîãî ââåäåíèÿ ïîëíàÿ èíàêòèâàöèÿ ïðåïàðàòà.
 ÏàáÌåäå ññûëîê íå íàøåë. |
#888
|
||||
|
||||
î÷åíü ïîäðîáíî îá ýòîì íåéòðàëèçàòîðå çäåñü:
A specific antidote for dabigatran: functional and structural characterization [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] ðåçóëüòàòû òåñòèðîâàíèÿ íà äîáðîâîëüöàõ: [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#889
|
|||
|
|||
Ýòîò àíòèäîò åùå íåèçâåñòíî, êîãäà ïîÿâèòñÿ íà ðûíêå. Íå ðàíüøå 2017.
Èññëåäîâàíèÿ II-III ôàçû åùå íå ñòàðòîâàëè. Áëèæå ê ôèíèøó àíòèäîòû ê êñàáàíàì. Portola Pharmaceuticals Begins Enrollment in Phase 3 Study of FDA-Designated Breakthrough Therapy Andexanet Alfa and Factor Xa Inhibitor XARELTO(R) [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#890
|
|||
|
|||
Ýòîò àíòèäîò åùå íåèçâåñòíî, êîãäà ïîÿâèòñÿ íà ðûíêå. Íå ðàíüøå 2017.
Èññëåäîâàíèÿ II-III ôàçû åùå íå ñòàðòîâàëè. Ê òîìó âðåìåíè îí, âîçìîæíî è íå ïîíàäîáèòñÿ. Áëèæå ê ôèíèøó àíòèäîòû ê êñàáàíàì. Portola Pharmaceuticals Begins Enrollment in Phase 3 Study of FDA-Designated Breakthrough Therapy Andexanet Alfa and Factor Xa Inhibitor XARELTO(R) [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#891
|
||||
|
||||
Èíîãäà ìîëîäûå ïàöèåíòêè ñïðàøèâàþò ïî ïîâîäó áåðåìåííîñòè ïîñëå ïåðåíåñ¸ííîãî Q-èíôàðêòà ìèîêàðäà. Ãäå ìîæíî ïî÷èòàòü ïðî ýòó òåìó?
|
#892
|
||||
|
||||
åñòü òàêàÿ ïóáëèêàöèÿ ïî òåìå:
Coronary artery disease and myocardial infarction in pregnancy: A review of epidemiology, diagnosis, and medical and surgical management [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] òî, ÷òî Âû ñïðàøèâàåòå, îïèñàíî â ðàçäåëå: SUBSEQUENT PREGNANCY
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#893
|
||||
|
||||
|
#894
|
||||
|
||||
Åùå íåäàâíèé îáçîð îò ïîëüñêèõ êîëëåã ñ ïîäðîáíûì ïëàíîì âåäåíèÿ:
Pregnancy after Acute Coronary Syndrome: A Proposal for Patients’ Management and a Literature Review [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#895
|
|||
|
|||
Îáðàòèëñÿ ïàöèåíò 30 ëåò, ñîâåðøåííî áåç æàëîá. Ïðè ïðîõîæäåíèè ìåä. êîìèññèè íà ïðàâà ïî ÝÊà ñëó÷àéíî âûÿâëåíà ÑÀ-áëîêàäà 2 ñò. òèï 1. Ïî ÕÌ íà ñèíóñîâîì ðèòìå ñ àäåêâàòíîé ÷ññ (ïðè íàãðóçêå äî 175 â ìèí., ñðåäíÿÿ è íî÷üþ è äíåì íîðìàëüíàÿ) áîëåå òûñÿ÷è ñòà ýïèçîäîâ ÑÀ-áëîêàäû 2 ñò 1 òèïà ñ ìàêñèìàëüíûì RR äî 1,9 ñåê., ïðè÷åì è äíåì òîæå ìíîæåñòâåííûå ýïèçîäû. Íè÷åì íå áîëååò, ÿçâåííîé áîëåçíè íå áûëî, ñèìïòîìîâ íèêàêèõ. Êàê íàñ÷åò âîæäåíèÿ àâòî?
|
#896
|
||||
|
||||
__________________
Àëåêñàíäð Èâàíîâè÷ ñ ïîæåëàíèÿìè êðåïêîãî çäîðîâüÿ |
#897
|
||||
|
||||
Âèðóñíûé ãåïàòèò â àêòèâíîé ôàçå ýòî àáñîëþòíîå ïðîòèâîïîêàçàíèå ê íàçíà÷åíèþ ñòàòèíîâ (íàïðèìåð, ïðè ÈÁÑ), íåçàâèñèìî îò ïîêàçàòåëåé ÀËÒ, ÀÑÒ?
Åñëè äàëüíåéøèå àíàëèçû ïîêàæóò îòñóòñòâèå ðåïëèêàöèè âèðóñà, òî ñòàòèí ìîæíî áóäåò íàçíà÷èòü? |
#898
|
||||
|
||||
Am J Med Sci. 2014 May 6. [Epub ahead of print]
Statins and Hepatitis C Virus Infection: An Old Therapy With New Scope. Rzouq F1, Alahdab F, Olyaee M. Author information 1Division of Gastroenterology and Hepatology, Department of Internal Medicine (FR, MO), University of Kansas Medical Center, Kansas City, Kansas; Mayo Clinic, Knowledge and Evaluation Research Unit (FA), Rochester, MN. Although their safety and efficacy have been extensively demonstrated, significant underutilization of statins is frequently seen in clinical practice for fears of hepatotoxicity. Research has not only shown statins' safety in patients with various forms of liver disease but also revealed the great benefits conferred by such therapy among liver disease patients. Chronic hepatitis C virus (HCV) infection is not an exception. In fact, evidence has pointed to a dysmetabolic syndrome in HCV-infected patients, which places them at an increased risk for cardiovascular disease and makes statins a life-saving therapy with excellent efficacy. Furthermore, statins have shown anti-HCV proliferative effects and other beneficial roles in different aspects of liver health, making them excellent drugs with minimal risks. In this review, we have discussed the newly described dysmetabolic syndrome associated with HCV infection, statins safety and efficacy in patients with chronic liver disease with special emphasis on HCV patients, the anti-HCV-proliferative effects of statins and finally, the benefits of statin therapy in other aspects of chronic liver disease.
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#899
|
||||
|
||||
åùå:
The safety of statin therapy has been documented in patients with HCV infection (13, 16, 17). ïî ññûëêå: [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#900
|
||||
|
||||
Êàêóþ ìàêñèìàëüíóþ ñóòî÷íóþ äîõó òîðàñåìèäà íà ñòàðò ìîæíî íàçíà÷èòü äëÿ ëå÷åíèÿ ÕÑÍ? 20 ìã òðèôàñà óòðîì åæäíåâíî ìîãó íàçíà÷èòü ïàöèåíòó ñ îò¸êàìè íèæíèõ êîíå÷íîñòåé è æèäêîñòüþ â áðþøíîé ïîëîñòè?
|